PT - JOURNAL ARTICLE AU - Iryna Sygaieva TI - Pollen asthma treatment: Comparative efficacy study DP - 2011 Sep 01 TA - European Respiratory Journal PG - p265 VI - 38 IP - Suppl 55 4099 - http://erj.ersjournals.com/content/38/Suppl_55/p265.short 4100 - http://erj.ersjournals.com/content/38/Suppl_55/p265.full SO - Eur Respir J2011 Sep 01; 38 AB - Background: Airborne pollen has always been one of the most common triggers of asthma, so there is vital need in efficient specific hyposensibilisation.Aims and objectives: Principal aim was to check efficacy of different combinations of inhaled corticosteroid/long-acting β2-agonist upheld by specific immunotherapy and/or montelukast.Methods: In open-label, randomized, parallel group, one-year panel study were involved 468 patients with pollen asthma (moderate-to-severe airflow limitations, bronchitis symptoms, and a history of exacerbations). All participants had completed allergy examination (prick skin test), immunologic, and functional assessment corroborating their asthma status. Participants were randomized in three equal groups, 156 patients each. First group got specific immunotherapy, second - montelukast (Singulair), and third – both treatments. Entire population received budesonide/formoterol (Symbicort Turbuhaler) as well.Results: After 52-week treatment first group exhibited strong remission in 68% patients assigned, second group – in 61% patients, and third group – in 79% patients. These changes were statistically independent of patient's age, sex, and smoking status (P<0.01).Conclusions: Budesonide/formoterol in conjunction with allergen-specific immunotherapy and montelukast proved to be the most successful combination for curing pollen asthma.